Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H22N2O |
Molecular Weight | 282.3801 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1CCC=C(C1)C2=CC(=NO2)C3=CC=C(C)C=C3
InChI
InChIKey=FOQRKFCLRMMKAT-UHFFFAOYSA-N
InChI=1S/C18H22N2O/c1-3-10-20-11-4-5-16(13-20)18-12-17(19-21-18)15-8-6-14(2)7-9-15/h5-9,12H,3-4,10-11,13H2,1-2H3
PD 144418 oxalate is a remarkably potent and selective sigma1 receptor ligand
having potential antipsychotic properties. PD 144418 oxalate displayed
an apparent affinity (Ki) of 0.08 nM for sigma1 sites in guinea pig
brain membranes and a Ki of 1377 nM for sigma2 sites in rodent
neuronal NG108-15 cell membranes. PD 144418 oxalate was classified as sigma1 receptor antagonist based upon several assays, including
the ability to attenuate mescaline-induced scratching in mice. PD 144418 oxalate attenuates cocaine-induced hyperactivity in mice. It showed potential antipsychotic activity, but no antidepressant or
anxiolytic actions.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25100754 | https://www.ncbi.nlm.nih.gov/pubmed/9144641
Curator's Comment: In vivo, PD 144418 oxalate bound to central and peripheral σ1 sites in mouse, with an ED50 of 0.22 umol/kg in whole brain. It antagonizes mescaline-induced scratching in mice following i.p. administration. Also attenuates cocaine-induced hyperactivity in mice.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641
Curator's Comment: # Akunne HC et al., Pfizer (formerly Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, USA)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL287 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641 |
0.08 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641
Mice: the effects of PD 144418 oxalate (1
and 10 mg/kg) on cocaine-stimulated (1, 3 and 10 mg/kg)
locomotor activity was evaluated. PD 144418(10 mg/kg)
was also tested against haloperidol (0.1, 0.3 and 1 mg/
kg)-induced suppression of locomotor activity. In each
study, PD 144418 oxalate was administered 30 min prior to
testing, and cocaine or haloperidol was administered
10 min before the 1 hr locomotor activity test. All
injections were i.p.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9144641
PD 144418 oxalate
reversed the NMDA-induced increase in cGMP
levels with IC50 value of 4.5 uM in rat cerebella
slices.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
154130-99-1
Created by
admin on Sat Dec 16 17:29:17 GMT 2023 , Edited by admin on Sat Dec 16 17:29:17 GMT 2023
|
PRIMARY | |||
|
DTXSID90703437
Created by
admin on Sat Dec 16 17:29:17 GMT 2023 , Edited by admin on Sat Dec 16 17:29:17 GMT 2023
|
PRIMARY | |||
|
FV9595VZB7
Created by
admin on Sat Dec 16 17:29:17 GMT 2023 , Edited by admin on Sat Dec 16 17:29:17 GMT 2023
|
PRIMARY | |||
|
PD 144418
Created by
admin on Sat Dec 16 17:29:17 GMT 2023 , Edited by admin on Sat Dec 16 17:29:17 GMT 2023
|
PRIMARY | |||
|
53447361
Created by
admin on Sat Dec 16 17:29:17 GMT 2023 , Edited by admin on Sat Dec 16 17:29:17 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD